 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || pamapimod (RO4402257) / Roche
P2 data, Journal: The KINETIC phase 2 randomized controlled trial of oral pamapimod-pioglitazone in non-critically ill COVID-19 inpatients. (Pubmed Central) - Oct 25, 2023
The clinical trial was stopped for futility, mainly due to a lower-than-expected incidence of the primary endpoint. KIN001 was safe and well-tolerated but had no significant effect on clinical outcome.
- |||||| pamapimod (RO4402257) / Roche
Trial completion date, Trial suspension, Trial primary completion date: The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2 (clinicaltrials.gov) - Oct 5, 2023
P2, N=400, Suspended, Sponsor: Kinarus AG
KIN001 was safe and well-tolerated but had no significant effect on clinical outcome. Trial completion date: Oct 2023 --> Oct 2025 | Recruiting --> Suspended | Trial primary completion date: May 2023 --> May 2025
- | pamapimod (RO4402257) / Roche
New P2 trial: The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2 (clinicaltrials.gov) - Dec 21, 2022
P2, N=400, Recruiting, Sponsor: Kinarus AG
- | KIN001-CV / Kinarus
Journal: Characterization of the basement membrane in kidney renal clear cell carcinoma to guide clinical therapy. (Pubmed Central) - Nov 29, 2022
It showed that the HRS group exhibited stronger chemoresistance to chemotherapeutics like FR-180204, GSK1904529A, KIN001-102, and YM201636...All results suggested that FREM2 could be a potential candidate for KIRC prognosis prediction. In this study, we established a valid model and presented new therapeutic targets for the KIRC prognosis prediction as well as the clinical treatment recommendation, and finally, facilitated precision tumor therapy for every single individual.